Warning Labels The Surgeon General’s report led to the Federal ... The efficacy and acceptability of pharmacological ...

Researchers have tested a novel therapeutic concept to treat virus-induced lung failure in patients with severe COVID-19 in a phase 2 clinical trial. The approach may also be applicable to other ...

A new clinical study shows that an inhibitor of Fas ligand (FasL), also called CD95 ligand (CD95L), led to a faster recovery ...

Label-free biosensor assay detects Toll-like receptor signals and even discriminates between different signaling pathways.

Recently, I have been scrutinizing nutrition and supplement labels more than I normally do ... depression and has an ...

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Welcome to Tarsus’ Third Quarter 2024 Financial Results ...

Popular weight-loss drugs are helping some runners lose weight and crush PRs. Experts have some real concerns.

NeurAxis (NYSE:NRXS) announced today that the FDA granted an expanded 510(k) clearance for its IB-Stim non-implanted nerve ...

A new clinical study shows that an inhibitor of Fas ligand (FasL), also called CD95 ligand (CD95L), led to a faster recovery ...

Celiac Quebec (Cœliaque Québec) is co-organizing a first citizens' forum that will bring together patients, various ...

Brilaroxazine is generally well tolerated to date in patients with acute and stable schizophrenia – – Topline data from 1-year open-label extension (OLE) trial now expected in December 2024 – ...

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression completed enrolment of the double-blind phase in Q3 2024Phase 1 ...